Health&Life Co

Health&Life Co Capital Expenditures

The Capital Expenditures (CapEx) of Health&Life Co (1781.TWO) as of Nov 6, 2026 is -8.20 M TWD. In the previous year, Capital Expenditures (CapEx) was -2.85 M TWD — a change of 187.64% (lower).

Capital Expenditures

-8.20 MTWD

YoY

187.64%

Last updated:

Capital Expenditures (CapEx) of Health&Life Co is 2025 -8.20 M TWD. Capital Expenditures (CapEx) of Health&Life Co was 2024 -2.85 M TWD. It decreases by 187.64% lower compared to the previous year.

The Health&Life Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-4.24 M TWD
Jan 1, 2019
-61.57 M TWD
Jan 1, 2020
-34.10 M TWD
Jan 1, 2021
-13.89 M TWD
Jan 1, 2022
-12.32 M TWD
Jan 1, 2023
-8.09 M TWD
Jan 1, 2024
-2.85 M TWD
Jan 1, 2025
-8.20 M TWD
The Health&Life Co Capital Expenditures history
YEARCapital ExpendituresYoY
-8.20 MTWD+187.64%
-2.85 MTWD-64.80%
-8.09 MTWD-34.30%
-12.32 MTWD-11.32%
-13.89 MTWD-59.26%
-34.10 MTWD-44.62%
-61.57 MTWD+1,353.81%
-4.24 MTWD-18.31%
-5.18 MTWD-59.11%
-12.68 MTWD-34.49%
-19.35 MTWD+140.36%
-8.05 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Capital Expenditures (CapEx) of Health&Life Co is -8.20 M TWD in 2025.

Capital Expenditures (CapEx) of Health&Life Co changed from -2.85 M TWD to -8.20 M TWD, representing a 187.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Health&Life Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Health&Life Co

All Key Metrics — Health&Life Co